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Background: &KURQLF IXQFWLRQDOFRQVWLSDWLRQ LVDFRPPRQSUREOHP WKDWDIIHFWVEHWZHHQRI WKH
population and cause symptoms and disorders that creates discomfort, morbidity, and high costs for health 
care. Recently, the consumption of probiotics in treating chronic constipation in adults have been investigated. 
However, there are still limited and controversial evidences available from controlled trials. The aim of this 
study was to evaluate the effects of Lactobacillus reuteri (L. reuteri) in improving the Agachan constipation 
score, the number of L. reuteri in the feces and the fecal pH in the patients with chronic functional constipation.
Method: $GRXEOHEOLQGSODFHERUDQGRPL]HGFRQWUROOHGWULDO5&7ZDVFRQGXFWHGLQDGXOWVPDOHV
IHPDOHVZLWKPHDQDJH\HDUVDIIHFWHGE\FKURQLFIXQFWLRQDOFRQVWLSDWLRQDFFRUGLQJWR5RPH,,,FULWHULD
Patients were randomly assigned to receive a supplementation of L. reuteri or placebo for 4 weeks.
Results: $WZHHNWKHGHFUHDVHLQ$JDFKDQFRQVWLSDWLRQVFRUHZDVIURPWRZLWKSWKH
LQFUHDVHQXPEHURI/UHXWHULZDVIURP[WR[ZLWKSDQGWKHGHFUHDVHRIS+IHFHV
ZDVIURP6'WR6'ZLWKSLQWKH/UHXWHULJURXSRWKHUZLVHLQWKHSODFHERJURXS
WKHUHZHUHQRVLJQL¿FDQWUHVXOWVLQ$JDFKDQFRQVWLSDWLRQVFRUHWKHQXPEHURI/UHXWHULDQGIHFDOS+DVVHVVHG
Conclusion: L. reuteri is more effective than the placebo group in improving the Agachan constipation score, 
increasing the number of L. reuteri in the feces and decreasing the fecal pH in adult with chronic functional 
constipation.
Keywords: Agachan constipation score, constipation, Lactobacillus reuteri (L. reuteri), fecal pH, polymerase 
chain reaction (PCR).
$%675$.
Latar belakang: Konstipasi fungsional kronik adalah masalah yang sering ditemukan di masyarakat dengan 
SUHYDOHQVLVHNLWDU.RQVWLSDVLPHQLPEXONDQEHUEDJDLJHMDODPHQLQJNDWNDQDQJNDNHVDNLWDQGDQELD\D
kesehatan. Saat ini, penggunaan probiotik untuk pengobatan konstipasi kronik pada dewasa telah diteliti, namun, 
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dari berbagai penelitian yang telah dilakukan hasil yang diperoleh masih terbatas dan menimbulkan kontroversi. 
Tujuan penelitian ini adalah untuk menilai manfaat Lactobacillus reuteri (L. reuteri) dalam memperbaiki skor 
konstipasi Agachan, jumlah L. reuteri feses dan pH feses pada pasien konstipasi fungsional kronik.
Metode: 8MLDFDNWHUVDPDUJDQGDGLODNXNDQSDGDSDVLHQGHZDVDODNLODNLSHUHPSXDQUHUDWDXVLD
WDKXQ\DQJPHQGHULWDNRQVWLSDVLIXQJVLRQDONURQLNVHVXDLNULWHULD5RPH,,,VHODQMXWQ\DGLODNXNDQ
randomisasi dan diberikan L. reuteri atau plasebo selama 4 minggu.
Hasil: Pada minggu ke-4, setelah pemberian L. reuteri terjadi perbaikan gejala konstipasi, yang dinilai 
GDULSHQXUXQDQVNRUNRQVWLSDVL$JDFKDQGDULPHQMDGLGHQJDQS7HUMDGLSHQLQJNDWDQMXPODK/
UHXWHULIHVHVGDUL[PHQMDGL[GHQJDQSGDQSHQXUXQDQS+IHVHVGDUL6%
PHQMDGL6%GHQJDQSSDGDNHORPSRN/UHXWHULVHGDQJNDQSDGDNHORPSRNSODVHERWLGDN
didapatkan hasil yang bermakna pada perbaikan skor konstipasi Agachan, jumlah L. reuteri feses dan pH feses.
Simpulan: L. reuteri lebih efektif dibandingkan plasebo dalam memperbaiki konstipasi, meningkatkan jumlah 
L. reuteri feses dan menurunkan pH feses pada pasien konstipasi fungsional kronik dewasa.
Kata kunci: skor konstipasi Agachan, konstipasi, Lactobacillus reuteri (L. reuteri), pH feses, polymerase 
chain reaction (PCR).
producing bacteria. Short-chain fatty acids lower pH of 
feces that will trigger increased intestinal motility and 
the frequency of defecation, deconjugation intestinal 
bile acids and increased water and minerals absorption, 
that will have effect on softening of stool. Several 
studies have reported that probiotics administration 
will increase intestinal motility and the frequency of 
defecation.11,12,13,14 Futhermore, probiotics also can 
accelerate transit time of feces in the intestine, thus 
improving symptoms of constipation, which lead to 
improvement in the Agachan scores, as well as safe for 
use in patients with chronic constipation. Lactobacillus 
reuteri is one of commonly used probiotics.3,15,16,17
However, several studies report that probiotics do 
not give good results in patients with constipation. 
Coccurullo et al, Tabbers et al, and An et al reported 
WKDWWKHUHLVQRVLJQL¿FDQWGLIIHUHQFHVLQWKHIUHTXHQF\
and consistency of defecation in patients taking 
probiotics.16,18,19 This research was conducted because 
of the differences in the reported results of various 
studies on the use of L. reuteri in chronic constipation 
patients, and the lack of research on chronic constipation 
in adult patients which were assessed based on various 
aspects of constipation.
0(7+2'
This study is an experimental study with double-
blind randomized trials. Subjects were divided into 
two groups, which are group A who are given L. 
reuteri and group B who are given placebo. This study 
was conducted in Cipto Mangunkusumo Hospital 
Jakarta, Bogor Medical Center Hospital, and Bina 
Husada Hospital Cibinong from April 2015 to May 
,1752'8&7,21
Chronic functional constipation is a gastrointestinal 
complain in form of bloating, constipation, abdominal 
pain that occured at least 12 weeks, in 6 months, 
without any organic or biochemistry disorder.1,2 
Chronic functional constipation have an impact on 
activity and give the sense of discomfort that will 
decrease the patients’ quality of life, as well as give 
KLJKULVNRIKHPRUUKRLGVDQDO¿VVXUHVDQGFRORUHFWDO
cancer occurance.1,3 Prevalence of chronic functional 
constipation is about 15-25% of the population.3 
In Cipto Mangunkusumo Hospital Jakarta, from 
patients undergone colonoscopy procedure, 9% 
of them are constipation patients.4 Treatment of 
chronic constipation which consists of long-term use 
of laxatives can lead to decreased gastrocolic and 
GXRGHQRFROLF UHÀH[ WKHUHIRUH FDXVHG GHSHQGHQFH5 
Therefore, it was necessary for a long-term alternative 
WKHUDSK\RSWLRQVZKLFKDUHEHQH¿FLDODQGVDIHRQH
of them is by utilize the microbiota in the intestine. 
Human intestine contains various commensal 
and pathogenic microbiota. If the commensal and 
pathogenic microbiota in intestine balance is impaired 
intestinal pathogens, will cause gastrointestinal 
motility disorders and hardening of the stool that will 
cause constipation.3,6,7,8,9
Probiotics are live microorganisms when consumed 
LQ DGHTXDWH DPRXQWVZLOO SURYLGH KHDOWK EHQH¿WV
including for the treatment of constipation.3,10 The use 
of probiotics for the treatment of chronic functional 
constipation recently received much attention. The 
most common used probiotics are Lactobacillus and 
%L¿GREDFWHULXPwhich are short-chain fatty acids 
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2015. Sampling was done by consecutive sampling 
technique with simple random sampling method. 
The sample size was calculated using the formula 
sample size for analytical research with numerical 
unpaired data, so that it was found that there must be 
20 patients in every group. The inclusion criteria for 
this study are patients with age more than 18 years old, 
meet the Rome III criteria for constipation, increased 
VWRROFRQVLVWHQF\XQVDWLV¿HGGHIHFDWLRQVHQVDWLRQRI
DQRUHFWDOREVWUXFWLRQXVHRI¿QJHUVWRKHOSGHIHFDWLRQ
defecate less than three times per week, not suffering 
from depression, absent of organic disorder in the colon 
which proven by colonoscopy, and provide writing 
consent to participate in this study. The exclusion 
criteria for this study are patients with age more than 
65 years old, post-stroke patients, pregnant patients, 
suspected organic constipation, depression, patients 
with alarm symptoms, consumption of laxative drugs, 
patients who given antibiotics theraphy, presence of 
neurological disorders in the spinal cord of S2–S4, 
rectum disorders, and refused to give consent to 
participate in the study.
Forty constipation outpatients from Cipto 
Mangunkusumo Hospital (Jakarta), Bogor Medical 
Center Hospital, and Bina Husada Hospital (Cibinong), 
who meet the inclusion criteria are randomized. Patient 
history was taken for demographic data, medical history, 
drug history. Physical examination and cosntipation 
assessment with Agachan constipation score are done. 
Patients were given a sterile tube for stool specimen 
collection. Stool samples collection procedure 
described in the appendix. Stool samples were sent to 
the microbiology laboratory of Faculty of Medicine, 
University of Indonesia/Cipto Mangunkusumo 
Hospital using a special container with temperatures 
cooler to check Lactobacillus reuteri bacteria and 
feces pH. The examination procedure of Lactobacillus 
reuteri using the polymerase chain reaction (PCR) 
method described in the appendix. Then, the patient 
were given treatment with drugs with code A or 
drugs with code B which containing Lactobacillus 
reuteri 2 x 108 colony-forming unit (CFU) or placebo 
respectively, according to the results of randomization. 
Drugs taken 2 times a day for 4 weeks.
The data were processed using SPSS version 
20. Variables with normal distribution were tested 
using unpaired t-test while variables with abnormal 
distribution were tested using Wilcoxon test. The 
GLIIHUHQFHVZHUH FRQVLGHUHG VWDWLVWLFDOO\ VLJQL¿FDQW
if the value of p < 0.05 was obtained. This study was 
approved by the health research ethics committee of 
Faculty of Medicine, University of Indonesia.
5(68/76
During the study, it was found 40 subjects of chronic 
functional constipation patients, of which 6 subjects are 
from Gastroenterology Clinical Cipto Mangunkusumo 
Hospital (Jakarta), 25 subjects are from Bogor Medical 
Center Hospital, and 9 subjects from Bina Husada 
Hospital (Cibinong). Subjects were divided into two 
groups, 20 subjects (50%) were given placebo and 20 
subjects (50%) were given L. reuteri, and there was 
no drop out subject. Ranges of Agachan scores before 
treatment in placebo and L. reuteri group are 16.00 
(15-19), dan 17.00 (16-20) respectively. Ranges of 
numbers of L. reuteri before treatment in placebo and 
L. reuteri group are 1.34 x 108  (1.07 x 106-1.43 x 109)/
gram feces and 6.80 x 107 (3.23 x 107- 9.85 x 109)/gram 
feces respectively. Means of feces pH before treatment 
are 5.39 (+ 0,75) in placebo group and 5.44 (+ 0.70) 
in L. reuteri group. Characteristics of subjects before 
treatment can be seen in Table 1.
There is a significant difference in Agachan 
scores in Lactobacillus reuteri group before and after 
WUHDWPHQWZKLOHWKHUHLVQRVLJQL¿FDQWGLIIHUHQFHLQ
placebo group, as shown by Table 2.
7DEOH$JDFKDQVFRUHVLQSODFHERDQGLactobacillus reuteri 
JURXSEHIRUHDQGDIWHUWUHDWPHQW
*URXS $JDFKDQVFRUH p*%HIRUH $IWHUZHHNV
Placebo 16.00 (15-19) 16.0 (15-19) 0,132
Lactobacillus reuteri 17.00 (15-20) 8.00 (4-13)  < 0,001
*Wilcoxon test
7DEOH&KDUDFWHULVWLFVRIVXMHFWVEHIRUHWUHDWPHQW
&KDUDFWHULVWLF *URXS p3ODFHERQ  L. reuteriQ 
Sex
Male
Female
6 (50)
14 (50)
6 (50)
14 (50)
1.000
Age (years old), mean (SD) 39.45 (14.86) 45.95 (16.74) 0.202
Feces pH before treatment, mean (SD) 5.39 (0.75) 5.44 (0.70) 0.831
Agachan score before treatment, range (min-max) 16.0 (15-19) 17.0 (16-20) 0.050
Numbers of L. reuteri/gram feces before treatment, range (min-max) 1.34x108  
(1.07x106 – 1.43x109)
6.80x107  
(3.23x107 – 9.85x109)
0.298
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Improvement of Agachan score’s components in 
placebo and Lactobacillus reuteri groups are shown 
by Table 3.
7DEOH&KDQJHVLQFRPSRQHQWVRI$JDFKDQVFRUHVLQSODFHER
DQGLactobacillus reuteri JURXSEHIRUHDQGDIWHUWUHDWPHQW
9DULDEOHVRI
$JDFKDQVFRUH
3ODFHER L. reuteri
%HIRUH $IWHUZHHNV %HIRUH
$IWHU
ZHHNV
Frequency of 
defecation
2 (1-3) 2 (1-3) 2 (1-3) 1 (0-1)
'LI¿FXOW\RIGHIHFDWLRQ 3 (2-3) 3 (2-3) 3 (2-4) 1 (0-3)
Uncompleteness of 
defecation
3 (2-4) 3 (2-4) 3 (3-4) 2 (0-3)
Abdominal pain 3 (2-4) 3 (2-4) 3 (2-4) 1 (0-3)
Time in the toilet 3 (2-4) 3 (2-4) 2 (1-3) 2 (1-3)
Assistance needed for 
defation
1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2)
Failure of defecation 2 (1-3) 2 (1-3) 1 (1-2) 0 (0-1)
Duration of costipation 1 (0-3) 1 (0-3) 1 (0-4) 1 (0-4)
Numbers of Lactobacillus reuteri in both groups are 
not balanced, so that Wilcoxon test was used. There 
LVDVLJQL¿FDQWGLIIHUHQFHLQQXPEHUVRILactobacillus 
reuteri in Lactobacillus reuteri group before and after 
WUHDWPHQWZKLOHWKHUHLVQRVLJQL¿FDQWGLIIHUHQFHLQ
placebo group, as shown by Table 4.
7DEOH  1XPEHUV RILactobacillus reuteri LQ SODFHER DQG
Lactobacillus reuteri EHIRUHDQGDIWHUWUHDWPHQW
*URXS
1XPEHUVRIIHVHVL. reuteri  
3&5JUDPIHFHV p*
%HIRUH $IWHU
Placebo 1.34x108  
(1.07x106 – 1.43x109)
1.35x108  
(1.11x108 – 1.41x108)
0.955
Lacto-
bacillus 
reuteri
6.80x107  
(3.23x107 – 9.85x109)
2.12x109  
(2.26x107 – 5.07x1011)
< 0.001
*Wilcoxon test
Measurement of feces pH in two groups given 
normally distributed data, therefore unpaired t-test 
ZDVXVHG7KHUH LV D VLJQL¿FDQW GLIIHUHQFH LQ IHFHV
pH in Lactobacillus reuteri group before and after 
WUHDWPHQWZKLOHWKHUHLVQRVLJQL¿FDQWGLIIHUHQFHLQ
placebo group, as shown by Table 5.
7DEOH)HFHVS+IHVHVLQSODFHERDQGLactobacillus reuteri 
JURXSEHIRUHDQGDIWHUWUHDWPHQW
*URXS )HFHVS+ p*%HIRUH $IWHU
Plasebo 5.39 (SD 0.75) 5.45 (SD 0.62) 0.588
Lactobacillus reuteri 5.44 (SD 0.70) 4.78 (SD 0.56) < 0.001
*unpaired t-test
7DEOH'LIIHUHQFHVRIGHOWDPHDQRIIHFHVS+GHOWDPHGLDQRI
$JDFKDQVFRUHDQGPHGLDQQXPEHUVRILactobacillus reuteri 
EHWZHHQSODFHERDQGLactobacillus reuteri JURXS
9DULDEOH *URXS p*3ODFHER L. reuteri
Delta feces pH, 
mean (SD)
0.05  
(SD 0.42)
-0.66  
(SD 0.46)
< 0,.001
Delta Agachan 
score, median 
(range)
0.0  
(-1.0 – 1.0)
-10.0  
(-14-(-3.0))
< 0.001*
Delta numbers 
of Lactobacillus 
reuteri, median 
(range)
8.0 x 104  
(-7.09 x 107 – 3.4 x 107)
2.02 x 109  
(-7.09 x 107 – 3.4 x 107)
< 0,001*
*unpaired t-test
7KHUHDUHVLJQL¿FDQWGLIIHUHQFHVRIGHOWDPHGLDQRI
Agachan score, numbers of Lactobacillus reuteri and 
feces pH between placebo and Lactobacillus reuteri 
group before and after treatment (p < 0.001). These 
results can be seen in Table 6.
',6&866,21
In this study, female subjects are more than male 
subjects. Study by Yang et al reported that constipation 
are occured more in female than in male with ratio 4:1. 
This difference is caused by females who are more 
often exposured to anxiety, work fatigue, volatile 
emotions, and inactivity.11,20
,QWKLVVWXG\LWZDVIRXQGWKDWWKHUHLVVLJQL¿FDQW
difference in Agachan score in Lactobacillus reuteri 
group before and after treatment compared with 
placebo group. Improvement in defecation pattern 
occured in components of defecation frequency 
GLI¿FXOW\LQGHIHFDWLRQXQFRPSOHWHQHVV
of defecation (90%), abdominal pain (85%), time in 
toilet (50%), assistance in defecation (100%), failure in 
defecation (100%) and duration of constipation (0%). 
This result is according to report of Waitzberg et al 
which found that improvement in Agachan score in 
patients which are given synbiotic.15 Several studies in 
use of probiotic in constipation reported that there are 
VLJQL¿FDQWLPSURYHPHQWVLQIUHTXHQF\RIGHIHFDWLRQ
intestinal motility, and stool consistency. Ojetti et al, 
Coccorullo et al, and Indrio et al reported that there are 
VLJQL¿FDQWLPSURYHPHQWLQGHIHFDWLRQIUHTXHQF\LQWKH
fourth week after Lactobacillus reuteri administration. 
Yang et al, Guera et al, Guyonnet et al, and Piano 
et al reported that there are increased in defecation 
frequency and improvement in stool consistency with 
%L¿GREDFWHULXP administration.3,6,14,11,21,22,23 From several 
studies which already been conducted, assessment only 
done in several components of constipation, which are 
defecation frequency, stool consistency and abdominal 
pain, however in this sudy, assessment was done in 
PDQ\FRPSRQHQWVZLWKVLJQL¿FDQWUHVXOW
,QWKHVWXG\E\7DEEHUVHWDOWKHUHLVQRVLJLQL¿FDQW
improvement in defecation frequency in children whose 
given %L¿GREDFWHULXP, whereas the study by Bekkali 
et al UHSRUWHGWKDWWKHUHLVVLJQL¿FDQWLPSURYHPHQWLQ
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defecation requency, but there is no improvement in 
stool consistency.18,24 Difference in results found by two 
studies mentioned above is becaused the sudies conducted 
in children in which there are differences in constipation in 
children and adults in terms of onset, etiology, symptoms, 
treatment and prognosis. The study by An et al reported 
that there is increased in defecation frequency in 
elderly patients whose given L. reuteri, but it was 
XQVLJQL¿FDQW WKLV FDXVHGE\KLJK ULVN RI LPRELOLW\
polypharmacy, and other chronic diseased owned by 
the elderly patients. This difference with this study is 
the age ranges of patients in this study are 39.45 tahun 
(± 14.86) for female patients and 45.95 tahun (± 16.74) 
for male patients.19
In this study, numbers of L. reuteri in feces 
LQFUHDVHG VLJQL¿FDQWO\ LQL. reuteri group in fourth 
ZHHNDIWHU WKH WUHDWPHQW EXW WKHUH LV QR VLJQL¿FDQW
difference in placebo group. This result is according 
to the study by Wolf et al which reported that there is 
VLJQL¿FDQWLQFUHDVHGLQQXPEHUVRIL. reuteri in feces in 
patients whose given L. reuteri in seventh, fourteenth, 
DQGWZHQW\¿UVWGD\17 The same result also reported by 
Lidbeck et al and An et al.25 Study by Spanhaak et al 
reported that administration of 109 CFU Lactobacillus 
in healthy adults can increased the numbers of 
Lactobacillus as much as 107/gram feses and decreased 
the numbers of Clostridium bacteria. This result 
showed that there is balance between comensal and 
pathogenic bacteria in intestine.26 Bu et al reported 
that there is increased of Lactobacillus in feces 
after Lactobacillus casei rhamnosus administration, 
but it was not related to defecation frequency.27 The 
difference in the results are probably by different strain 
of Lactobacillus which used in each study.
Numbers of consumpted L. reuteri can affect 
numbers of L. reuteri in feces. Bu et al reported that 
L. reuteri must be given in dose of 109-1010 CFU per 
day in order to be detected in feces. In this study, 
the patients were given 2 x 108 CFU Lactobacillus 
reuteri and the numbers of L. reuteri in feces increased 
VLJQL¿FDQWO\27 Study by Sinkiewicz et al reported that 
women in Japan have higher prevalence of L. reuteri 
colonization compared to women in other countries, 
which probably cuased by consumption of functional 
foods, probiotics and various fermented foods in 
Japanese diet so that it can be concluded that the types 
RI IRRGVZLWKKLJK¿EHUDQG ORZ IDWPD\DIIHFW WKH
numbers of L. reuteri in intestine.28,29
Studies by Lee et al and Stewart et al reported that 
consumption of glutathione and inulin can increased 
numbers of L. reuteri in intestine. In our study, the 
assessment in patients’ diet was not done, therefore effect 
of diet to numbers of L. reuteri cannot be determined. 
However, in our study, both groups of subjects already 
informed not to consume foods that contain probiotic, 
fermented foods and several herbal medicines that 
will affect the study’s result.30,31 Feces pH in this 
VWXG\ZDV VLJQL¿FDQWO\GHFUHDVHGDIWHU WKH WUHDWPHQW
compared to placebo group. This result is according to 
result of Koebnick et al which reported Lactobacillus 
casei administration in children patients with chronic 
cosntipation can decreased feces pH.32 The decreased 
feces pH caused by production of acid forming bacteria. 
However, Spanhaak et al reported that there is no 
difference of feces pH in probiotic administraion so that 
the effect on intestinal motility is doubted.26
There is no side effect of L. reuteri administration 
in this study. The result is correspond with studies 
by Bekkali et al and Jones et al which reported that 
there is no side effect found in administration of 2.9 x 
109 L. reuteri for 9 weeks in constipation patients.24,26 
Futhermore, Bu et al reported that there is no side effect 
of Lactobacillus casei rhamnosus administration in 
children patients.24,26,27 L. reuteri can be considered as 
a treatment option for chronic functional constipation. 
Examination of feces L. reuteri feses can be used to 
assess number of feces L. reuteri in chronic functional 
constipation patients which given treatment of L. 
reuteri. Feces pH feses also can be used as examination 
to monitor L. reuteri administration in chronic 
functional constipation patients.
&21&/86,21
After L. reuteri administration for 4 weeks, it can 
be concluded that there are improvement in defecation 
pattern in chronic functional constipation patients, 
increased number of L. reuteri feces in chronic 
functional constipation patients, and pH reduction of 
feces in chronic functional constipation patients.
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